AZN (AstraZeneca PLC) Stock Financials & Earnings

Company Info & Key Metrics

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imf...

CEOPascal Claude Roland Soriot

Country🇬🇧 United Kingdom

ExchangeNYSE

IPOMay 12, 1993

www.astrazeneca.com

Revenue$15.5B

YoY Growth+4.1%

QoQ Growth+2.1%

Net Income$2.3B

EPS$0.74

Free Cash Flow$1.4B

Gross Margin79.9%

Op. Margin19.2%

Net Margin15.0%

FCF Margin8.9%

Rev Multiple (TTM)5.2x

P/E Ratio (TTM)29.8x

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$10.9B	$9.0B	$2.5B
Q2 23	$11.4B	$9.5B	$2.5B
Q3 23	$11.5B	$9.4B	$2.0B
Q4 23	$12.0B	$9.7B	$1.2B
Q1 24	$12.7B	$10.5B	$3.1B
Q2 24	$12.9B	$10.8B	$2.7B
Q3 24	$13.6B	$10.5B	$2.1B
Q4 24	$14.9B	$12.2B	$2.0B
Q1 25	$13.6B	$11.3B	$3.7B
Q2 25	$14.5B	$12.0B	$3.5B
Q3 25	$15.2B	$12.4B	$3.6B
Q4 25	$15.5B	$12.4B	$3.0B

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	7.0x	64.9x
Q2 23	6.9x	49.5x
Q3 23	6.8x	51.7x
Q4 23	6.7x	51.2x
Q1 24	6.4x	48.2x
Q2 24	6.2x	47.4x
Q3 24	6.0x	47.0x
Q4 24	5.6x	43.4x
Q1 25	5.5x	39.3x
Q2 25	5.4x	36.8x
Q3 25	5.2x	32.5x
Q4 25	5.2x	29.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$3.1B	$1.7B
Q2 23	$1.7B	$1.2B
Q3 23	$3.1B	$2.2B
Q4 23	$2.4B	$1.4B
Q1 24	$2.5B	$881M
Q2 24	$3.1B	$2.4B
Q3 24	$3.4B	$2.0B
Q4 24	$2.9B	$2.0B
Q1 25	$3.7B	$3.3B
Q2 25	$3.4B	$1.5B
Q3 25	$5.1B	$4.4B
Q4 25	$2.4B	$1.4B

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$1.5B
Q2 23	$483M
Q3 23	$879M
Q4 23	$946M
Q1 24	$1.6B
Q2 24	$668M
Q3 24	$1.4B
Q4 24	$955M
Q1 25	$429M
Q2 25	$1.9B
Q3 25	$686M
Q4 25	$1.1B

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-4.5%	-20.8%
Q2 23	+6.0%	-12.4%
Q3 23	+4.6%	-2.0%
Q4 23	+7.3%	+6.7%
Q1 24	+16.5%	+14.8%
Q2 24	+13.3%	+13.8%
Q3 24	+18.0%	+20.1%
Q4 24	+23.8%	+19.1%
Q1 25	+7.2%	+3.7%
Q2 25	+11.7%	+7.4%
Q3 25	+12.0%	+1.3%
Q4 25	+4.1%	-2.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$0	0.0%
Q4 23	$579M	4.8%
Q1 24	$0	0.0%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$0	0.0%
Q1 25	$0	0.0%
Q2 25	$0	0.0%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$2.6B	$4.1B	$134M
Q2 23	$2.7B	$5.0B	$131M
Q3 23	$2.6B	$4.8B	$129M
Q4 23	$3.1B	$5.4B	$145M
Q1 24	$2.8B	$4.5B	$135M
Q2 24	$3.0B	$4.9B	$132M
Q3 24	$3.1B	$5.1B	$145M
Q4 24	$4.7B	$5.4B	$143M
Q1 25	$3.2B	$4.5B	$135M
Q2 25	$3.5B	$4.9B	$143M
Q3 25	$3.7B	$5.1B	$148M
Q4 25	$3.9B	$5.5B	$153M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$6.2B	$230M	$6.5B
Q2 23	$5.7B	$148M	$5.8B
Q3 23	$4.9B	$244M	$5.1B
Q4 23	$5.8B	$20M	$5.9B
Q1 24	$7.8B	$180M	$8.0B
Q2 24	$6.9B	$160M	$7.1B
Q3 24	$4.8B	$133M	$4.9B
Q4 24	$5.5B	$166M	$5.7B
Q1 25	$5.2B	$165M	$5.4B
Q2 25	$7.1B	$50M	$7.1B
Q3 25	$8.1B	$39M	$8.2B
Q4 25	$5.7B	$30M	$5.7B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	3.12B	+0.1%
Q2 23	3.12B	+0.0%
Q3 23	3.12B	+0.0%
Q4 23	3.12B	+0.1%
Q1 24	3.12B	-0.1%
Q2 24	3.12B	+0.0%
Q3 24	3.12B	+0.0%
Q4 24	3.12B	+0.1%
Q1 25	3.12B	-0.1%
Q2 25	3.12B	-0.1%
Q3 25	3.12B	+0.1%
Q4 25	3.12B	+0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$2.9B	9
FY 15	$2.7B	9
FY 16	$2.6B	9
FY 17	$112K	200K
FY 18	$110K	200K
FY 19	$122K	200K
FY 20	$133K	200K
FY 21	$187K	200K
FY 22	$222K	200K
FY 23	$229K	200K
FY 24	$27M	2K
FY 25	$29M	2K